The inhibitory effect of trastuzumab on BT474 triple‑positive breast cancer cell viability is reversed by the combination of progesterone and estradiol

Breast cancer expressing the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) is known as triple-positive (TPBC). TPBC represents 9–11% of breast cancer cases worldwide and is a heterogeneous subtype. Notably, TPBC presents a therapeutic challeng...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Méndez, José A., Ventura-Gallegos, José L., Camacho-Arroyo, Ignacio, Lizano, Marcela, Cabrera-Quintero, Alberto J., Romero-Córdoba, Sandra L., Martínez-Vázquez, Mariano, Jacobo-Herrera, Nadia J., León-Del-Río, Alfonso, Paredes-Villa, Adrian A., Zentella-Dehesa, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688505/
https://www.ncbi.nlm.nih.gov/pubmed/38034484
http://dx.doi.org/10.3892/ol.2023.14152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688505/
https://www.ncbi.nlm.nih.gov/pubmed/38034484
http://dx.doi.org/10.3892/ol.2023.14152

Ejemplares similares